A melanocortin receptor agonist approved for acquired, generalized low sexual desire in premenopausal women.
Key takeaway
Bremelanotide activates melanocortin receptors in the brain involved in sexual desire. It is a cyclic peptide related to alpha-MSH.
At a glance
| FDA status | In an FDA-approved drug |
|---|---|
| 503A compounding | Eligible for 503A compounding (component of an approved drug) |
| Body areas | Sexual & reproductive health, Brain, mood & sleep |
| Through ScriptMates | Prescribable by licensed providers |
| Open questions | None noted |
What is Bremelanotide (PT-141)?
Bremelanotide activates melanocortin receptors in the brain involved in sexual desire. It is a cyclic peptide related to alpha-MSH.
It is the active ingredient of FDA-approved Vyleesi, an injection for hypoactive sexual desire disorder in premenopausal women.
Dosage forms
FDA-approved Vyleesi is a solution for subcutaneous injection in a prefilled autoinjector. Compounded preparations are not FDA-approved.
Is Bremelanotide (PT-141) FDA-approved?
Active ingredient of FDA-approved Vyleesi. Compounded bremelanotide is not itself FDA-approved.
Can it be prescribed through ScriptMates?
Eligible for 503A compounding (component of an approved drug). A 503A partner pharmacy lists this peptide, and it has a lawful 503A compounding pathway.
Sources
Checked October 27, 2026. FDA updates these pages, so confirm before relying on them.